For Providers

Influenza Vaccine Information Statement:
English | Spanish

Seasonal Influenza Vaccination Resources for Health Professionals (CDC): HERE

Routine annual influenza vaccination is recommended for all persons over 6 months who do not have contraindications.

CDC Launches New Pneumococcal Vaccination App

As influenza activity picks up, we may also see increases in pneumococcal disease rates. Help protect your patients by making sure they are up to date with pneumococcal vaccination. CDC recently launched an app to help vaccination providers quickly and easily determine which pneumococcal vaccines a patient needs and when. The PneumoRecs VaxAdvisor mobile app incorporates recommendations for all ages and will especially help with interpreting vaccination recommendations based on medical indications. Users simply enter a patient’s age, note if the patient has specific underlying medical conditions, and answer questions about the patient’s pneumococcal vaccination history. Then the app provides patient-specific guidance consistent with U.S. Advisory Committee on Immunization Practices recommended immunization schedule.

Available for iOS and Android devices at

Prevention and Control of Seasonal Influenza with Vaccines: ACIP Recommendations for the 2018 – 2019 Influenza Season
This report updates the 2017–18 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2017;66[No. RR-2]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2018–19 season. Standard-dose, unadjuvanted, inactivated influenza vaccines will be available in quadrivalent (IIV4) and trivalent (IIV3) formulations. Recombinant influenza vaccine (RIV4) and live attenuated influenza vaccine (LAIV4) will be available in quadrivalent formulations. High-dose inactivated influenza vaccine (HD-IIV3) and adjuvanted inactivated influenza vaccine (aIIV3) will be available in trivalent formulations.
MMWR – August 24, 2018

For the 2018-2019 season:
– A/Michigan/45/2015 (H1N1)pdm09-like virus
– A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
– B/Colorado/06/2017-like virus (Victoria lineage)
Quadrivalent vaccines will contain these three viruses and an additional B/Phuket/3073/2013-like virus (Yamagata lineage)

  • Pregnant women may receive any licensed, recommended, age-appropriate vaccine
  • FluMist Quadrivalent (LAIV4) is being updated for the 2018-2019 season, and may be used this season
  • Monitoring during the 2018-2019 season will yield more safety monitoring data concerning pregnancy and influenza vaccinations and anaphylaxis in persons with an egg allergy.

MMWR June 8, 2018: Influenza Activity in the United States During the 2017 – 2018 Season

The United States 2017–18 influenza season (October 1, 2017–May 19, 2018) was a high severity season with high levels of outpatient clinic and emergency department visits for influenza-like illness (ILI), high influenza-related hospitalization rates, and elevated and geographically widespread influenza activity across the country for an extended period. Nationally, ILI activity began increasing in November, reaching an extended period of high activity during January–February, and remaining elevated through March. Influenza A(H3N2) viruses predominated through February and were predominant overall for the season; influenza B viruses predominated from March onward. This report summarizes U.S. influenza activity* during October 1, 2017–May 19, 2018. Read More.

Delaware Flu Season Summary 2017-2018